2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

801. Gene Therapies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Emerging Technologies, Gene Editing, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Transplantation, Vaccines, Gene Therapy, Immunotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Genomics, Diseases, Bleeding and Clotting, Hemophilia, Bone Marrow Failure Syndromes, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, B Cell Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

4305 Consistent collection, engraftment, and outcomes across pediatric and adult recipients of lovotibeglogene autotemcel clinical trials for sickle cell disease

Ashish Gupta, MD, MBBS, MPH, Julie Kanter, MD2, Anil George3, Robert Nickel, MD, MSc4, Elizabeth Krieger, MD5, Jennifer A Rothman I, MD6, Mahvish Rahim, MD7, Anjulika Chawla, MD8, Lin Pan9, Tong Shen10, Melissa Kinney11, Joanne Lager, MD12, Stacey Rifkin-Zenenberg, DO, MS13
1 University of Minnesota, Minneapolis, United States
2 University of Alabama at Birmingham, Birmingham, United States
3 Baylor College of Medicine, Houston, United States
4 Children’s National Health System, Washington, United States
5 VCU Medical Center, Richmond, United States
6 Duke University, Durham, United States
7 Montefiore Medical Center, Bronx, United States
8 Genetix Biotherapeutics, Somerville, United States
9 Genetix Biotherapeutics, Somerville, United States
10 Genetix Biotherapeutics, Somerville, United States
11 Genetix Biotherapeutics, Somerville, United States
12 Genetix Biotherapeutics, Somerville, United States
13 Hackensack University Medical Center, Hackensack, United States

Background: Lovotibeglogene autotemcel (lovo-cel) is approved for patients aged ≥12 years with sickle cell disease (SCD) and history of vaso-occlusive events (VOEs). Lovo-cel is a one-time autologous hematopoietic stem and progenitor cell gene therapy, in which CD34+ cells are transduced with lentiviral vector encoding modified β-globin gene (βA-T87Q), to produce anti-sickling adult hemoglobin A (HbAT87Q) with near-identical oxygen affinity to wild-type adult hemoglobin. As SCD is a lifelong disease, better understanding of the gene therapy process and treatment outcomes across age groups is warranted. We report new pooled clinical trial data for lovo-cel spanning the broadest age range (2 to 38 years) analyzed to date.

Methods: The HGB-206 study (NCT02140554) has been previously described (Kanter, et al. Am J Hematol. 2023;98:11-22; Kanter, et al. N Engl J Med. 2022;386:617-628). The ongoing HGB-210 study (NCT04293185) is similar but included pediatric patients aged ≥2 years. Upon completion of parent study, follow-up continues in the ongoing LTF-307 study (NCT04628585). Updated data are presented from trial participants treated with lovo-cel manufactured using the current commercial process, grouped by age at enrollment into <12, 12 to <18, and ≥18-year age groups. A subset of participants aged ≥25 years was also evaluated, representing approximately half of all adult participants. Outcomes included number of mobilization cycles and apheresis days required to meet target CD34+ cell dose, neutrophil and platelet engraftment, and globin response (Hb and HbAT87Q fraction of nontransfused total Hb). Complete resolution of VOE (VOE-CR) and severe VOE (sVOE-CR) during months 6–18 post lovo-cel infusion and VOE resolution for at least 12 consecutive months (VF12) were evaluated for participants with ≥4 VOEs at baseline and ≥18 months of follow-up. Durability of response and safety were assessed.

Results: Between February 2, 2015, and May 19, 2026, 81 participants enrolled and initiated mobilization across HGB-206 Group C (n=43) and HGB-210 (n=38). Median (range) age was 19 (2–38) years. 69 received lovo-cel (age range: 6–38 years; 6 to <12 years, n=12; 12 to <18, n=14; ≥18, n=43; ≥25, n=23) and duration of follow-up post lovo-cel was 62 (2.3–101.7) months. 10 participants could not mobilize/collect sufficient cells for drug product manufacturing, and 2 were pending treatment as of the data cut. Among the 69 participants treated, the median mobilization cycles was 1. The proportion of participants who required only 1 cycle increased with younger age (<12 years, 9/12 participants [75.0%]; 12 to <18, 7/14 [50.0%]; ≥18, 19/43 [44.2%]; ≥25, 7/23 [30.4%]). Across all participants, median total apheresis days required was 2 (<12 years, 2 days; 12 to <18, 2 days; ≥18, 2 days; ≥25, 3 days). Median time to neutrophil engraftment was 21 days (<12 years, 21.5 days; 12 to <18, 22.5 days; ≥18, 20 days; ≥25, 19 days), and time to platelet engraftment was 36 days (<12 years, 32 days; 12 to <18, 47.5 days; ≥18, 33 days; ≥25, 29 days).

Ninety-two percent (58/63) of evaluable participants achieved sustained globin response, and no graft failure was observed. The median (range) HbAT87Q % of nontransfused total Hb at year 5 was 44.74% (27.8%-57.4%). Eighty-eight percent (50/57) of evaluable participants achieved VOE-CR, and of these, 44 (88.0%) remained VOE free at last follow-up. 54 (94.7%) achieved sVOE-CR, and of these, 48 (88.9%) remained sVOE free at last follow-up. 56/57 (98.2%) achieved VF12. Outcomes were concordant across age groups, including among participants aged <12 and ≥25 years.

Safety was consistent with myeloablative conditioning and underlying SCD. A previously reported HGB-206 participant with 2 α globin deletions and reported MDS remains well >3 years after the MDS diagnosis without MDS therapy, maintains globin response, is free of VOEs, and has marrow findings consistent with dyserythropoiesis of hemoglobinopathy.

Conclusion: This analysis spans the broadest age range reported to date for SCD gene therapy including patients from 2-38 years of age. Cell collection success, engraftment, globin response, and VOE-CR/sVOE-CR were concordant across the treated age range. Updated post lovo-cel treatment data in pediatric participants (<12 years) data will be presented. These findings support lovo-cel as feasible and effective therapy across a wide age range of patients with SCD, including those aged <12 and ≥25 years.

Ashish Gupta, MD, MBBS, MPH: Emerging Therapies Solutions - Honoraria; Gentix Biotherapeutics - Research Funding; Jazz Pharmaceuticals - Research Funding; Beam Therapeutics - Research Funding; Orchard Therapeutics - Research Funding; Vertex Pharmaceuticals - Consultancy (Includes expert testimony)